The FDA approved Enspryng for thyroid eye disease, the first at-home subcutaneous option. Read how this new treatment works ...

CHMP issues second negative opinion on narsoplimab (Yartemlea) for TA-TMA, leaving European patients without an approved ...

ARPA-H awards Georgetown and Buck Institute up to $51.7M to build an AI platform predicting protein misfolding in Alzheimer's ...

First Tracks Biotherapeutics prices a $200M private placement at $32.75 per share to advance ANB033. Read the full details ...

Terumo and Oxford University launch a six-year, $9M+ organ perfusion research partnership. Discover how it could extend organ ...

OMass Therapeutics raised USD 310M (GBP 230M) in an oversubscribed Series C to push its MC2 antagonist into Phase II. Read ...

J&J and Triastek sign a collaboration, license and equity deal to develop novel 3D-printed oral medicines. Read the full ...

BioAge Labs and Deep Origin launch an AI-driven multi-target drug discovery deal, with validated hits in under 3 months. Read ...

Iambic Therapeutics prices IPO at $16 per share, raising $150M to advance AI-discovered HER2 inhibitor. Read the full details ...

Ocugen partners with Roots Pharmaceutical to bring OCU400 retinitis pigmentosa gene therapy to the Middle East and North ...

Verdiva Bio halted its Phase II trial of oral ecnoglutide (VRB-101) for weight maintenance after injectable GLP-1 therapy.

Eton Pharmaceuticals secures exclusive U.S. rights to Libervant, a diazepam buccal film for epilepsy seizure clusters. Read ...